<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="224768">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00156273</url>
  </required_header>
  <id_info>
    <org_study_id>UMCC 2003.075</org_study_id>
    <secondary_id>HUM 45808 Legacy 2004-0703</secondary_id>
    <nct_id>NCT00156273</nct_id>
  </id_info>
  <brief_title>Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer</brief_title>
  <official_title>A Pilot Study to Determine the Feasibility of Quantifying Apoptosis and Bcl-2 Expression in Circulating Tumor Cells (CTCs) in Women Undergoing Treatment for Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are trying to develop better ways to detect when cancer therapies are working.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2005</start_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the feasibility of detecting Bcl2 expression and apoptosis in CTCs</measure>
    <time_frame>Prospective</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        women with metastatic breast cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Females at least 18 years of age 2 Diagnosis of metastatic breast cancer 3.ECOG Score of
        0-2 4.Treating oncologist has decided to initiate any new systemic therapy with emphasis
        on recruiting patients commencing a taxane-based regimen. Taxine-based therapy may be
        docetaxel or paclitaxel, and it can be given on any schedule,including weekly or every 3
        weeks. Other treatment can include non-taxane chemotherapy or trastuzumab-with or without
        other therapy.

        5.Patient is willing to return for one or more additional ~18 mL blood draw (s) at 24-48-,
        and /or 72 hours and ~3-4 weeks after the initiation of therapy.At a minimum, patients
        must donate blood at baseline, one intermediate interval (24, 48, 72 hr) and at ~3-4 weeks
        6.Signed Informed Consent Form

        Exclusion Criteria:

        Patient is unable and unwilling to provide a blood specimen at a minimum of one of the
        intermediate blood draw time points at 24, 48, or 72 hours -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Smerage, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 2, 2016</lastchanged_date>
  <firstreceived_date>September 7, 2005</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
